Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1999 Dec;24(6):461-9.
doi: 10.1046/j.1365-2710.1999.00257.x.

Substance P Antagonists: The Next Breakthrough in Treating Depression?

Affiliations
Review

Substance P Antagonists: The Next Breakthrough in Treating Depression?

S Baby et al. J Clin Pharm Ther. .

Abstract

Several lines of evidence implicate the neuropeptide substance P in depression, either in the pathogenesis or as a novel target for amelioration of symptoms. NK1 (substance P) receptor antagonists have been reported to have antidepressant-like actions in animal models. The first clinical trial of an NK1 antagonist showed promising results. A second trial, using a more potent compound, is underway. If the clinical trials show that NK1 (substance P) antagonism represents a well-tolerated, distinct mechanism for antidepressant activity, novel antidepressant agents will emerge as mono- or adjunct-therapy.

Similar articles

See all similar articles

Cited by 5 articles

LinkOut - more resources

Feedback